Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
DEST.L Share News (DEST)
DEST Share
Price
DEST Share
News
DEST Share
Chat
DEST Share
Trades
DEST
Live RNS
DEST Share
Charts
DEST Broker
Ratings
DEST Directors
Deals
DEST Financial
Diary
DEST
Fundamentals
DEST Short
Positions
DEST
Media
DEST Company
Research
DEST Company
Timeline
- There is currently no data for DEST
DEST.L News
Destiny publishes 'important' research on its preoperative treatment candidate
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced the publication of landmark clinical data for 'XF-73' on Friday, in t...
IN BRIEF: Destiny Pharma raises GBP7.3 million total in equity raise
Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology - Gets 33% take-up of open offer of shares, raising GBP340,000. Destiny rais...
Destiny shares fall on fundraise discount despite USD570 million deal
(Alliance News) - Destiny Pharma PLC on Friday said that it has signed a collaboration agreement with Sebela Pharmaceuticals for NTCD-M3, its lead ass...
TRADING UPDATES: Appreciate gets court date; Corcel completes sale
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Destiny Pharma jumps on 2022 progress
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma updated the market on its progress in 2022 on Thursday, including working to fi...
LONDON MARKET MIDDAY: UK stocks rise as Paris and Frankfurt head lower
(Alliance News) - Stock prices in London were higher at midday on Thursday, ahead of some key US economic data, while equities elsewhere were less buo...
Destiny Pharma on track for commercial agreement for NTCD-M3 drug
(Alliance News) - Destiny Pharma PLC on Thursday said partnering negotiations for its NTCD-M3 clinical programme are nearing finalisation.
Destiny Pharma eyes potential billion dollar returns from Nasal asset
(Alliance News) - Destiny Pharma PLC on Wednesday said it has finalised development plans for phase three testing of its late-stage clinical asset, XF...
Follow the stocks
